Skip to content

Vascular Reparative Mechanism in Diabetes

Vascular Reparative Mechanism by ACE2/Ang-(1-7) in Diabetes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02119689
Acronym
RAAS
Enrollment
78
Registered
2014-04-22
Start date
2011-10-30
Completion date
2026-12-31
Last updated
2025-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Retinopathy

Keywords

Diabetes, Retinopathy

Brief summary

The purpose of this research study is to study blood stem cells in diabetic patients and normal patients. We would like to better understand if these cells, called endothelial precursor cells (EPCs), are not working as expected in people with diabetes. We would like to see if the function of these cells can predict the development of diabetic retinopathy. Diabetic retinopathy is an eye disease associated with diabetes in which the cells of the retina are damaged. It can cause blurred vision, vision loss, blindness or possible bleeding in the retina. Even with current treatments, the quality of life for people with diabetic retinopathy is much reduced.

Interventions

OTHERDiabetic Patients

measuring CD34 cell function in relation to diabetic retinopathy status

OTHERHealthy Controls

measuring CD34 cell function

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
University of Alabama at Birmingham
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Men or women 18 years or older * 39 type 1 or type 2 diabetic patients * 13 with mild retinopathy * 13 with moderate retinopathy * 13 with severe, nonproliferative retinopathy * 39 age and sex matched healthy controls

Exclusion criteria

* Current pregnancy as evidence by a urine pregnancy test as the blood from a pregnant female will influence the results of the laboratory tests

Design outcomes

Primary

MeasureTime frameDescription
The ACE/ACE2 ratio within EPC'sup to 216 weeksPeripheral blood of 150cc, approximately 8-10 tablespoons will be collected from a vein in the arm of both diabetic and healthy control patients.

Secondary

MeasureTime frameDescription
The balance of the RAS (renin-angiotensin system) within EPCsup to 216 weeksThe Endo-PAT2000 will be used to obtain this measurement. This is a 15-minute office-based test where a blood-pressure cuff is placed around the arm, inflated and measurements are obtained from a small fingertip monitor

Other

MeasureTime frameDescription
Photography findingsup to 216 weeksThe findings from eye photographs will be collected and evaluated from both the diabetic patients and the heallthy control patients. This will be done at either the patient's yearly visit or at their 6 week follow-up visit.
Fluorescein angiogram findingsup to 216 weeksThe findings from eye photographs will be collected and evaluated from both the diabetic patients and the heallthy control patients. This will be done at either the patient's yearly visit or at their 6 week follow-up visit.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026